Carpal tunnel syndrome.
Conditions
Interventions
Intervention 1: First intervention group: 120 mg Vitamin B6 Janilous pharmaceutical Co. daily and splint for 10 weeks. Intervention 2: Second intervention group: 1500 mg L-acetyl-carnitine Dana pharma
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: Patients with Mild or Moderate Carpal Tunnel Syndrome Disease Proved with Electrodiagnostic Study within Last 2 Months Patients Age Ranges from 30-60
Exclusion criteria
Exclusion criteria: Severe Carpal Tunnel Syndrome Muscle Atrophy History of Carpal Tunnel Syndrome surgery History of Trauma History of Fracture History of Direct Injection of Carpal Tunnel History of Recent Usage of Corticosteroids and Analgesics Diabetes Collagen Vascular Disorders Rheumatologic Disorders Active Radiculopathy Past Medical History of Brucellosis Pregnancy Lactation Alcoholism Nerve Injury Neuropathy Inability in Communication and Fulfilling Questioners History of Allergic Reaction to Studied Medications History of Significant Liver, Kidney or Cardiovascular Disease Cancer History of Injection Around Wrist within 3 Last Months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Latency of Median sensory nerve action potential. Timepoint: Before the treatment, 10 and 18 weeks after beginning treatment. Method of measurement: Electromyography-Nerve conduction study (EMG-NCV) machine.;Score of clinical symptoms (like pain and paresthesia) in questionnaires. Timepoint: Before the treatment, 10 and 18 weeks after beginning treatment. Method of measurement: Visual Analogous Scale and Boston Carpal Tunnel Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNavid Parsa
Shiraz University of Medical Sciences
Outcome results
None listed